Trade

Sun Pharma Advanced Research Company Ltd share price

Balanced risk
  • 40%Low risk
  • 40%Moderate risk
  • 40%Balanced risk
  • 40%High risk
  • 40%Extreme risk
  • 138.30(-0.54%)
    February 9, 2026 15:29:57 PM IST
    • NSE
    • BSE
  • Vol : 860.92 K (NSE + BSE)
    Last 20 day avg : 894.44 K

Sun Pharma Advanced Research Company Ltd is trading -0.54% lower at Rs 138.30 as compared to its last closing price. Sun Pharma Advanced Research Company Ltd has been trading in the price range of 143.70 & 136.40. The company posted a net profit of -75.85 Crores in its last quarter.Listed peers of Sun Pharma Advanced Research Company Ltd include Cipla (0.88%), Dr Reddy's Laboratories (2.49%), Torrent Pharmaceuticals (1.48%).The Mutual Fund holding in Sun Pharma Advanced Research Company Ltd was at 0.76% in 31 Dec 2025. The MF holding has decreased from the last quarter. The FII holding in Sun Pharma Advanced Research Company Ltd was at 2.04% in 31 Dec 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Feb 09, 2026, 04:52 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.80
    High volatility
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
136.40
Highest
143.70
52 week range
Lowest
109.20
Highest
204.25
Sun Pharma Advanced Research Company Ltd Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Cipla
Moderately Bearish
1,342.450.881,08,439.3222.953.870.870.81
Dr Reddy's Laboratories
Bullish
1,272.002.491,06,121.5418.633.140.632.34
Torrent Pharmaceuticals
Bullish
3,998.051.481,35,582.0667.3217.10.8317.62
Sun Pharmaceutical Industries
Neutral
1,702.700.474,08,476.9436.245.770.920.50
Divi's Laboratories
Moderately Bearish
6,116.401.521,62,315.9778.6111.520.460.01
Mutual Fund Ownership
View all
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 63.63
  • % of AUM 1.16
Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.76
  • % of AUM 0.24
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.03
  • % of AUM 0.15
Mirae Asset Nifty Total Market Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.01
  • % of AUM 0.01
Bandhan Nifty Total Market Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.01
  • % of AUM 0.01
Sun Pharma Advanced Research Company Ltd Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-02-09Quarterly Results
2026-01-14To consider issue of Warrants & ESOP
2025-11-10Quarterly Results
2025-08-04Quarterly Results
2025-05-19Audited Results
About the company Sun Pharma Advanced Research Company Ltd
  • IndustryBiotechnology & Drugs
  • ISININE232I01014
  • BSE Code532872
  • NSE Code
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. Its lead therapeutic agent, vodobatinib (SCC-138), is a c-ABL inhibitor that has the potential to be a therapy modulating cellular homeostasis in neurodegenerative diseases. Vibozilimod (SCD-044) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist targeting autoimmune disorders. SCD-153 is a topical agent being developed for the treatment of alopecia areata. SBO-154 is an ADC being developed for multiple tumor types expressing MUC-1.
  • Management Info
  • Anilkumar RaghavanChief Executive Officer
  • Anup RathiChief Financial Officer
  • Kajal DamaniaCompliance Officer, Company Secretary
Sun Pharma Advanced Research Company Ltd Share Price FAQs

Sun Pharma Advanced Research Company Ltd is trading at 138.30 as on Mon Feb 09 2026 09:59:57. This is -0.54% lower as compared to its previous closing price of 139.05.

The market capitalization of Sun Pharma Advanced Research Company Ltd is 4467.25 Cr as on Mon Feb 09 2026 09:59:57.

The 52 wk high for Sun Pharma Advanced Research Company Ltd is 204.25 whereas the 52 wk low is 109.20

Sun Pharma Advanced Research Company Ltd can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: -
  • Dividend Yield: %
  • D/E ratio: -

Sun Pharma Advanced Research Company Ltd reported a net profit of -342.51 Cr in 2025.

The Mutual Fund Shareholding was 0.76% at the end of 31 Dec 2025.